Aurobindo Pharmas Q1 net up 40% at Rs 636 Cr

Aurobindo Pharmas Q1 net up 40% at Rs 636 Cr Hyderabad,Aug 7 (PTI): Aurobindo Pharma reported a nearly 40 per cent jump in its net profit (after JV share, minority interest)to Rs 636 crore for the quarter ended June 30 against Rs 456 crore for the same quarter last fiscal. Revenue from operations grew 28 per cent to Rs 5444.6 crore during the quarter under discussion against Rs 4250 crore in Q1FY19, it said.

N Govindarajan, Managing Director of the company said: "We have started the year with a healthy performance. Enhancing our quality management practices and adhering to the regulatory requirements continues to be our highest priority.

During the quarter, we have commissioned Eugias manufacturing facility and launched 5 Oncology and Hormonal products in the US market. Our differentiated product basket is progressing well and we are in the process of starting clinical trials for our first biosimilar in Q2FY20." US Formulations revenue for Q1FY20 witnessed a growth of 42.3 per cent on year on year basis to Rs 2,688.4 crore, accounting for 49.4 per cent of consolidated revenue EU formulations revenue in the quarter witnessed a growth of 16.1 per cent YoY to Rs 1,391.6 crore, accounting for 25.6 per cent of consolidated revenue, it said..